Last reviewed · How we verify
Warfarin titrated to an INR of 2.5-3.0
Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver.
Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver. Used for Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, Treatment and prevention of deep vein thrombosis and pulmonary embolism.
At a glance
| Generic name | Warfarin titrated to an INR of 2.5-3.0 |
|---|---|
| Sponsor | US Department of Veterans Affairs |
| Drug class | Vitamin K antagonist |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Warfarin acts as an anticoagulant by inhibiting the gamma-carboxylation of vitamin K-dependent clotting factors, which are essential for blood coagulation. This results in a decrease in the production of these clotting factors, leading to a reduction in blood clotting.
Approved indications
- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
- Treatment and prevention of deep vein thrombosis and pulmonary embolism
Common side effects
- Bleeding
- Nosebleeds
- Bruising
- Gastrointestinal bleeding
- Hemorrhagic stroke
Key clinical trials
- Long-term Safety in Atrial Fibrillation Patients (PHASE2)
- Warfarin and Antiplatelet Therapy in Chronic Heart Failure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: